Lake Bluff, IL, United States of America

Jieyi Wang

USPTO Granted Patents = 22 (Patent Applications = 10)

CIPO Patents = 2 (Patent Applications = 14)

EPO Patents = 9 (Patent Applications = 21)

Average Co-Inventor Count = 3.7

ph-index = 7

Forward Citations = 282(Granted Patents)

Location History:

Gurnee, IL (US) (2001 - 2009)
Lake bluff, IL (US) (2005 - 2015)
Belmont, CA (US) (2017 - 2024)

Company Filing History:

9 out of 4,177

Abbott Laboratories Corporation

Lyvgen Biopharma Holdings Limited

patents

4. 2 out of 51

Abbvie Biotherapeutics Inc.

patents

5. 1 out of 1

Lyvgen Biopharma Co., Ltd.

patent

6. 1 out of 1

Lyvgen Biopharma (suzhou) Co., Ltd.

patent

where one patent can have more than one assignee

Years Active: 2001-2024

Loading Chart...

22 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12024560 - Therapeutic agents and methods for enhancing immune responses in tumor microenvironment (2024-07-02),

2. 11976123 - Anti-CD40 antibodies and uses thereof (2024-05-07),

3. 11505615 - Anti-CD137 antibodies and uses thereof (2022-11-22),

4. 11203643 - Humanized anti-CD137 antibodies and uses thereof (2021-12-21),

5. 11186648 - Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereof (2021-11-30),

6. 10913797 - Anti-PD-1 antibodies and therapeutic uses thereof (2021-02-09),

7. 10875921 - Anti-4-1BB antibodies and their uses (2020-12-29),

8. 10383948 - Anti-cMet antibody drug conjugates and methods for their use (2019-08-20),

9. 10184003 - Prolactin receptor binding proteins and uses thereof (2019-01-22),

10. 9725515 - Prolactin receptor binding proteins and uses thereof (2017-08-08),

11. 9029508 - Dual variable domain immunoglobulins and uses thereof (2015-05-12),

12. 8536180 - Pyrimidine inhibitors of kinase activity (2013-09-17),

13. 8486933 - Pyrimidine inhibitors of kinase activity (2013-07-16),

14. 8354422 - Pyrimidine inhibitors of kinase activity (2013-01-15),

15. 8067409 - Protein kinase inhibitors (2011-11-29),

Title: Innovations in Immunotherapy: The Contributions of Jieyi Wang

Introduction

Jieyi Wang, based in Lake Bluff, IL, is a prolific inventor in the field of immunotherapy, with a remarkable portfolio comprising 22 patents. His groundbreaking work focuses on therapeutic agents and methods aimed at enhancing immune responses within the tumor microenvironment, contributing significantly to advancements in treating cancer and immune disorders.

Latest Patents

Among his latest patents, one is titled "Therapeutic agents and methods for enhancing immune responses in tumor microenvironment - Human IgG1, IgG2, and IgG4 mutants having mutations in the hinge domain and exhibiting altered binding activity to Fcγ receptors such as FcγRIIB." This patent details methods for selectively activating immune responses by targeting specific immune cell surface receptors. Another noteworthy patent is "Anti-CD40 antibodies and uses thereof," where he discloses agnostic anti-CD40 antibodies designed to enhance CD40 signaling and, consequently, immune responses. These inventions are pivotal in the treatment strategies for diseases, notably cancer and various immune disorders.

Career Highlights

Jieyi Wang has made substantial contributions during his tenure at notable companies like Abbott Laboratories Corporation and AbbVie Inc. His innovative work has not only advanced the field of immunotherapy but has also established him as a leading figure in developing new treatment paradigms.

Collaborations

Throughout his career, Jieyi has collaborated with esteemed professionals, including George S. Sheppard and Megumi Kawai. These collaborations have fostered an environment of creativity and innovation, enabling the development of novel therapeutic interventions.

Conclusion

Jieyi Wang’s contributions to the field of immunotherapy through his patents reflect a commitment to enhancing treatment methodologies for complex diseases. His work continues to inspire the next generation of researchers and inventors striving to make a significant impact in medicine.

This text is generated by artificial intelligence and may not be accurate.